5 Dementia Medications that are Approved or in Clinical Trials

1. Leqembi

Topping the list of 10 dementia medications that are approved or in clinical trials, is Leqembi, which is manufactured and sold by Eisai and BioArctic. It is one of the most promising drugs for dementia currently and was only given approval by the FDA in January 2023. According to the press release by the FDA “Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” said Billy Dunn, M.D., director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research. “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.” The drug obtained approval under the Accelerated Approval pathway, which is a process which can fast track drugs being manufactured for serious conditions where there is currently not an adequate solution.

According to Reuters, Leqembi’s coverage by Medicare is likely to cost the U.S. government around $5 billion every year, and recently, Health Canada also accepted a submission by the two pharma companies for Leqembi’s filing for review. There will be a further stringent review by the FDA on July 6 at which point the agency will take the decision on whether it wants to grant a full nod to the promising drug. The application is currently based on results from a phase 3 trial conducted globally, where its efficacy in reducing cognitive decline in Alzheimer patients was proven.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out our articles on 20 Biggest Blockchain Companies in the World in 2023 and Top 20 Exporting Countries of 2022.